Emergent BioSolutions Inc.EBSNYSE
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -29.61% | -26.03% | -44.68% | -21.34% | -23.63% |
| Gross Profit Growth | -19.33% | -15.20% | +0.00% | -15.10% | -77.22% |
| EBITDA Growth | +0.00% | +12.57% | +0.00% | -1.54% | -67.14% |
| Operating Income Growth | +0.00% | +25.38% | +0.00% | +18.60% | +0.00% |
| Net Income Growth | +0.00% | +655.56% | +0.00% | -55.40% | +0.00% |
| EPS Growth | +0.00% | +635.29% | +0.00% | -55.56% | +0.00% |
| EPS Diluted Growth | +0.00% | +600.00% | +0.00% | -55.83% | +0.00% |
| Weighted Average Shares Growth | +4.43% | +4.21% | +3.04% | +0.19% | -1.29% |
| Weighted Average Shares Diluted Growth | +4.43% | +9.77% | +3.04% | +1.62% | +4.61% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -348.91% | +0.00% | +124.00% | -101.50% | +0.00% |
| Free Cash Flow Growth | -494.20% | +0.00% | +141.26% | -103.85% | +0.00% |
| Receivables Growth | -19.11% | -12.76% | -59.35% | +23.25% | -45.50% |
| Inventory Growth | -5.23% | -5.82% | +6.65% | +10.41% | +10.17% |
| Asset Growth | -23.87% | -20.93% | -6.37% | -1.14% | -5.61% |
| Book Value per Share Growth | -28.80% | -20.12% | +34.71% | +14.36% | +9.66% |
| Debt Growth | -22.95% | -27.81% | -22.89% | -1.91% | -15.38% |
| R&D Expense Growth | -69.05% | +0.00% | -61.77% | -2.17% | +32.97% |
| SG&A Expenses Growth | -32.10% | -37.85% | -43.08% | -48.75% | -16.80% |